CNS Clinical Trials: Suicidality and Data Collection: Workshop Summary
Forum on Neuroscience and Nervous System Disorders
The Food and Drug Administration (FDA) now requires that all clinical trials for drugs that affect the central nervous system--including psychiatric drugs--are assessed for whether that drug might cause suicidal ideation or behavior. The Institute of Medicine's (IOM) Forum on Neuroscience and Nervous System Disorders hosted a meeting on June 26, 2009, to discuss the FDA's new policy and how to analyze best whether suicidal thoughts predict actual suicidal behavior in the near future.
Categories:
Year:
2010
Edition:
1
Publisher:
National Academies Press
Language:
english
Pages:
88
ISBN 10:
0309148839
ISBN 13:
9780309148832
File:
PDF, 732 KB
IPFS:
,
english, 2010